ArticleCureus2025
Evaluation of Serum Neudesin Levels in Patients With Adrenal Incidentaloma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeudesin is a neurotrophic factor involved in various metabolic and inflammatory pathways. However, its role in adrenal incidentalomas remains unclear. This study aimed to evaluate serum neudesin levels in patients with adrenal incidentalomas and investigate their potential clinical significance. METHODOLOGY: This is a single-center, cross-sectional, controlled study conducted in the Endocrinology Clinic of Izmir Tepecik Training and Research Hospital between July 2018 and August 2019. The study included 68 patients diagnosed with adrenal incidentaloma and a control group of 38 healthy individuals. Age, gender, body mass index (BMI), adrenocorticotropic hormone (ACTH), cortisol, dehydroepiandrosterone sulfate (DHEA-S), total testosterone, plasma aldosterone, plasma renin activity, 24-hour urine metanephrine and normetanephrine levels, and neudesin levels were measured, and comorbidities were recorded.
resultsThe patient group was significantly older and had a higher BMI than the control group (
conclusionsOur findings suggest that serum neudesin levels may be associated with adrenal incidentalomas and related metabolic alterations. Further studies should investigate the potential diagnostic or prognostic value of neudesin in adrenal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.